Pcsk 9 Sirna denied as non-formulary by Cigna?

Cigna's specific coverage criteria for pcsk9 sirna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies a PCSK9 siRNA Agent as Non-Formulary

Cigna's formulary for a given plan year may list one PCSK9-directed agent as preferred while placing others — including siRNA-mechanism agents — on a non-preferred specialty tier or outside the formulary entirely. When your prescriber orders the non-preferred agent, Cigna's system generates a non-formulary denial. This is a coverage-tier determination, not a clinical judgment that the drug is inappropriate — and it can be overcome through the formulary-exception process when there is a clinical reason the formulary alternative is not suitable for you.

## Why This Denial Is Appealable

Federal rules require plans to maintain a meaningful formulary-exception process. If the formulary alternative — typically a PCSK9 monoclonal antibody — is clinically inappropriate for you due to a documented intolerance, a factor in your clinical history, or a clinical distinction your prescriber believes is medically important, you have grounds for a formulary exception. ACA §2719 and ERISA §503 govern the appeals process. External review is available if the internal exception and appeal are denied, generally within 4 months of the denial.

## The Appeal Process and Timeline

1. Identify the formulary alternative: obtain the current Cigna formulary for your specific plan and confirm which PCSK9-directed agent is preferred. Your prescriber should evaluate whether it is clinically appropriate for you. 2. Request a formulary exception: your prescriber submits a letter explaining why the siRNA agent is medically necessary and why the formulary alternative is not appropriate for your situation. 3. File Level 1 internal appeal if the exception is denied, within the deadline on the denial notice. 4. Request external review if the internal appeal is unsuccessful.

## Documentation to Gather

• Prescriber exception letter: a detailed explanation of why the siRNA agent is appropriate for you and why the formulary alternative is clinically inferior or unsuitable, based on factors documented in your chart.
• Trial or intolerance history: if you have already tried the formulary PCSK9 monoclonal antibody, provide pharmacy records and chart notes documenting the outcome — inadequate response or documented adverse effect.
• Clinical profile: diagnosis records, relevant lab history, and treating-clinician notes characterizing your cardiovascular condition and risk, framed around the applicable guideline organization's recommendations.
• FDA prescribing labels for both agents: if there is a clinically meaningful pharmacological or pharmacokinetic difference between the two agents that your prescriber considers relevant, citing the respective labels supports the exception.
• Cigna's formulary-exception criteria: request the specific criteria document from Cigna so every requirement can be addressed in the submission.

## Criteria-Mapping Structure

Your exception request and appeal should mirror Cigna's exception criteria exactly. For each criterion — typically covering prior use of the formulary alternative, documented intolerance or inadequate response, and prescriber attestation of medical necessity — provide the matching chart record or prescriber statement with a date and source. Attach pharmacy records and chart notes as numbered exhibits. A complete, organized submission is the most reliable path to a favorable formulary-exception decision.